Clinical Trial Update: Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating SSR180711C in mild Alzheimer's disease has been terminated according to the clinical trial update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• SSR180711C

Snippet

Sponsor: Sanofi | Conditions: Alzheimer's Disease | Phase 2 | Status: TERMINATED